Ocugen Execs Hit With Derivative Suit Over Shoddy Controls

By Sydney Price · July 18, 2024, 6:46 PM EDT

The top brass at biopharmaceutical company Ocugen Inc. were hit with a derivative suit alleging the company's lack of effective internal financial controls caused it to be misvalued and allowed shareholders...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Garg v. MUSUNURI et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

July 17, 2024

Recent Articles By Sydney

July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division
July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud
July 08, 2024
UnitedHealth Brass Face Investor Suit Over Merger Probe
July 08, 2024
Medical Device Co. SeaStar Sued Over Regulatory Disclosures
July 02, 2024
Pharma Co. Scores Exit In Investor Suit Over Primate Imports
June 06, 2024
Pharma Co. Misled Investors On Seizure Drug Trial, Suit Says
May 15, 2024
UnitedHealth Concealed DOJ Merger Investigation, Suit Says
May 13, 2024
Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
May 08, 2024
Shockwave Medical Investor Challenges $13B Deal With J&J
May 07, 2024
Pharma Co. Falsely Touted Obesity Drug Results, Suit Claims